Incidence of type 2 diabetes, hypertension, and dyslipidemia in metabolically healthy obese and non-obese. by Fingeret, M. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Incidence of type 2 diabetes, hypertension, and dyslipidemia in
metabolically healthy obese and non-obese
Authors: Fingeret M, Marques-Vidal P, Vollenweider P
Journal: Nutrition, Metabolism and Cardiovascular Diseases
DOI: 10.1016/j.numecd.2018.06.011
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
1 
 
Incidence of type 2 diabetes, hypertension, and dyslipidemia in metabolically 
healthy obese and non-obese 
Running title: Metabolically Healthy Obesity 
Fingeret M1, Marques-Vidal P2, Vollenweider P2 
1NYU School of Medicine, New York, NY, USA; 2Department of Internal Medicine, Lausanne 
University Hospital (CHUV), Lausanne, Switzerland 
Authors’ emails: 
Margo Fingeret:  Margo.Fingeret@nyumc.org 
Pedro Marques-Vidal: Pedro-Manuel.Marques-Vidal@chuv.ch 
Peter Vollenweider:  Peter.Vollenweider@chuv.ch 
 
Address for correspondence and reprints 
 Pedro Marques-Vidal 
 Office BH10-642, Department of Medicine, internal medicine 
Lausanne University Hospital (CHUV) 
Rue du Bugnon 46 
1011 Lausanne 
 Switzerland 
 Phone: +41 21 314 72 65 
 Fax:  +41 21 314 73 73 
 Email:  Pedro-Manuel.Marques-Vidal@chuv.ch 
 
 
 
Word count: 3566 
Number of tables: 3  Figures: 1  References: 33   
Number of supplemental tables: 3 
 
2 
 
ABSTRACT 
Background and Aims: Metabolically healthy obese (MHO) individuals are devoid of many 
metabolic abnormalities, but how this condition is maintained over time remains debated. We 
assessed the prevalence of MHO over time and the incidence of hypertension (HTN), 
dyslipidemia, and type 2 diabetes mellitus (T2DM) in MHO as compared with metabolically 
healthy non obese (MHNO). 
Methods and Results: Prospective, population-based study including 3038 participants 
(49.9±9.9 years; 1753 women) free from metabolic syndrome and cardiovascular disease at 
baseline and examined after a follow-up of 5.6 years and 10.9 years on average. At each 
follow-up, prevalence of MHO, MHNO, metabolically unhealthy not obese (MUNO), and 
metabolically unhealthy obese (MUO), as well as of HTN, dyslipidemia, and T2DM, was 
calculated and stratified by sex, age group, and education. 
At baseline, 179 (5.7%) MHO participants were identified, of which 62 (34.6%) and 79 (44.1%) 
remained MHO at 5.6 and 10.9 years follow-up, respectively. At 5.6 years follow-up, MHO 
participants were more likely to develop low HDL or be on hypolipidemic medication 
[multivariable-adjusted OR (95% CI): 1.56 (1.02-2.38)], to have dyslipidemia [1.94 (1.33-2.82)], 
and high triglycerides [2.07 (1.36-3.14)] than MHNO. At 10.9 years follow-up, MHO participants 
were significantly more likely to develop T2DM [3.44 (1.84-6.43)], dyslipidemia [1.64 (1.14-
2.38)], and low HDL or be prescribed hypolipidemic medication [1.57 (1.08-2.27)] than MHNO. 
Conversely, no differences were found regarding hypertension. 
Conclusion: A considerable fraction of MHO individuals lose their status over time, and in 
metabolically healthy adults, obesity confers a higher risk of developing cardiovascular risk 
factors. 
Abstract word count: 249 
Keywords: obesity; metabolically healthy obese; prospective; metabolic syndrome; 
dyslipidemia; hypertension; type 2 diabetes mellitus; epidemiology; Switzerland. 
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INTRODUCTION 
 Despite efforts to combat obesity, its prevalence, along with the prevalence of its 
associated cardiovascular risk factors (CVRFs), such as dyslipidemia, type II diabetes mellitus 
(T2DM), and hypertension (HTN), remains high [1]. In fact, such CVRFs continue to be 
responsible for an overwhelming number of deaths worldwide [2, 3]. Recent studies have 
identified various obesity phenotypes, notably metabolically healthy obese (MHO) individuals, 
who are devoid of multiple CVRFs, and metabolically unhealthy obese (MUHO), who present 
with many CVRFs. [4-6] However, the prevalence of MHO, as well as the comparative 
incidence of CVRFs and mortality, depends on the definition of metabolic syndrome applied, 
as there is little consensus on gold standard criteria for categorizing individuals as 
metabolically healthy or unhealthy obese [7, 8]. Indeed, in a previous study on a Caucasian 
cohort, we showed that the prevalence of the MHO phenotype ranged between 3.3 and 32.1% 
in men and between 11.4 and 43.3% in women [7]. Further work has also found a substantial 
prevalence of MHO in other ethnic groups [9, 10]. 
Several studies have suggested that MHO is an unstable condition, commonly leading 
to the development of metabolic abnormalities, but results have been inconsistent [4, 5, 11-
13]. In fact, few prospective studies have focused on the natural course of MHO. The bulk of 
these studies focused primarily on endpoints of cardiovascular disease (CVD), T2DM, and all-
cause mortality but reported contradictory results [12, 14-17]. Even fewer have examined the 
evolution of MHO as it concerns the incidence of dyslipidemia, T2DM, and HTN for MHO in 
comparison to that for metabolically healthy non-obese (MHNO) individuals. Clearly, the MHO 
state, along with its implications, remains poorly understood. 
Thus, the aims of this study were to assess the prevalence of metabolically healthy 
obesity and the incidence of HTN, dyslipidemia, and T2DM in the MHO as compared with that 
in the MHNO after a 10-year follow-up in an adult Swiss population-based sample. 
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PARTICIPANTS AND METHODS 
Participants 
Participants were from the CoLaus study, a prospective study intended to evaluate the 
prevalence of CVRFs and to identify genetic determinants of these risk factors in a Swiss 
population aged between 35 and 75 years at baseline [18]. Sampling was performed as 
follows: the source population was defined as all subjects within the age range of interest 
registered in the population register of the city of Lausanne, Switzerland. The register includes 
all subjects living in this city for more than 90 days. A simple, non-stratified random sample of 
19’830 subjects (corresponding to 35% of the source population) was drawn and the selected 
subjects were invited to participate by letter. If no answer was obtained, a second letter was 
sent, and if no answer was obtained, the subjects were contacted by phone. 
Inclusion criteria were: (a) written informed consent; (b) willingness to take part in the 
examination and to provide blood samples; (c) Caucasian origin; (d) French language ability. 
For this study, we added the following inclusion criteria: (a) participants who completed the 
baseline, first, and second follow-up examinations and (b) availability of all variables analysed. 
For eligibility, we excluded (a) metabolically unhealthy participants (obese and non-obese) at 
baseline, as defined by Joint Interim Statement (JIS) criteria (see below for more details) and 
(b) type 1 diabetics at baseline. We further excluded (a) participants with cardiovascular 
disease at baseline; (b) participants with missing data at baseline; (c) participants without 
follow-up and (d) participants with missing data at follow-up. 
Recruitment began in June 2003 and ended in May 2006, enrolling 6733 participants 
who underwent an interview, a physical exam, and a blood analysis. The first follow-up was 
performed between April 2009 and September 2012, 5.6 years on average after the collection 
of baseline data. The second follow-up was performed between May 2014 and July 2016, 10.9 
years on average after the collection of baseline data. The information collected was similar to 
that collected in the baseline examination but contained questions regarding food consumption 
and detailed physical activity information. 
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Methods 
All participants were examined in the morning after a fast of at least 8 hours. They were 
probed about their personal and family history of CVD, CVRFs, and cardiovascular treatment. 
CVD status at baseline was confirmed by further checking the available information provided 
by the participants (i.e. doctors, hospital registers, etc.). Smoking status was defined as never, 
former (no matter how long before the interview) and current. Educational level was 
categorized as low (primary), middle (apprenticeship), upper middle (high school), and high 
(university) for highest completed level of education. Physical activity was defined by 
answering positively to exercising 2 or more times per week for at least 20 minutes per session. 
Body weight and height were measured while participants stood without shoes in light 
indoor attire. Body weight was measured in kilograms to the nearest 100 g using a Seca® 
scale (Hamburg, Germany) that was frequently calibrated. Height was measured to the nearest 
5 mm using a Seca® (Hamburg, Germany) height gauge. Waist circumference was measured 
mid-way between the lowest rib and the iliac crest using a non-stretchable tape. The average 
of two measurements was taken and rounded to the nearest 0.5 cm. Blood pressure (BP) was 
measured thrice using an Omron® HEM-907 automated oscillometric sphygmomanometer 
after at least a 10 minute rest in a seated position, and the average of the last two 
measurements was used. 
Venous blood samples (50 mL) were drawn in the fasting state. Most biological assays 
were performed at the clinical laboratory of the Lausanne university hospital (CHUV) within 2 
hours of blood collection on fresh samples. Glucose was assessed by glucose dehydrogenase 
with a maximum inter- and intra-assay CV of 2.1% and 1.0%, respectively; total cholesterol by 
CHOD-PAP (1.6%–1.7%); HDL-cholesterol by CHOD-PAP + PEG + cyclodextrin (3.6%–
0.9%); triglycerides by GPO-PAP (2.9%–1.5%). 
Definition of variables and outcomes 
Obesity was defined per World Health Organization (WHO) guidelines and convention 
as having a body mass index (BMI), calculated as weight in kilograms divided by height in 
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meters squared, as ≥30 kg/m2 [19]. Non-obesity was defined as BMI <30 kg/m2. To classify 
individuals as metabolically healthy or not healthy, we applied criteria outlined in the Joint 
Interim Statement (JIS) for Caucasian individuals in 2009. The criteria are as follows: (a) fasting 
plasma glucose ≥5.6 mmol/L or drug treatment; (b) fasting TG ≥1.7 mmol/L or drug treatment; 
(c) fasting HDL-C <1.30 mmol/L in women and <1.00 mmol/L in men or drug treatment; (d) 
Systolic blood pressure (SBP) ≥130 mm Hg, diastolic blood pressure (DBP) ≥85 mm Hg, or 
drug treatment; (e) waist circumference of ≥102 cm for men and ≥88 cm for women [20]. Per 
JIS recommendations, subjects with 2 or fewer of the JIS criteria were defined as metabolically 
healthy while subjects meeting 3 or more of the criteria were defined as metabolically unhealthy 
and thus suffering from metabolic syndrome [20]. Antihypertensive drug treatment was defined 
if the participant took any medication for high blood pressure. Lipid-lowering medication was 
defined if the participant took any medication listed under the Anatomical Therapeutic 
Chemical (ATC) classification as a C10 agent. Anti-diabetic drug treatment was defined if the 
participants took any medication to lower blood glucose. 
When calculating the incidence of T2DM, dyslipidemia, and HTN, we did not take self-
reported physician diagnoses into account given that many participants in our sample were 
diagnosed at the time of study. T2DM was defined as fasting plasma glucose ≥7.0 mmol/L 
and/or anti-diabetic drug treatment, per WHO guidelines [21]. HTN was defined two ways: (a) 
≥140/90 mm Hg and (b) ≥130/85 mm Hg to consider both a less strict criterion for HTN and 
the JIS criterion. Dyslipidemia was broken down into: (a) fasting HDL-C <1.30 mmol/L in 
women and <1.00 mmol/L in men or drug treatment; (b) fasting TG ≥1.7 mmol/L; (c) any of the 
above criteria [20]. 
Ethical approval 
The institutional Ethics Committee of the University of Lausanne, which afterwards 
became the Ethics Commission of Canton Vaud (www.cer-vd.ch) approved the baseline 
CoLaus study (reference 16/03). The approval was renewed for the first (reference 33/09) and 
the second (reference 26/14) follow-ups. The study was performed in agreement with the 
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Helsinki declaration and its former amendments, and all participants gave their signed 
informed consent before entering the study. 
Statistical analysis 
Statistical analyses were performed using Stata version 14.2 for windows (Stata Corp, 
College Station, Texas, USA). Bivariate analyses were performed using chi-square or Fisher’s 
exact test for qualitative variables and Student’s t-test. In the bivariate comparisons, results 
were expressed as number of participants (percentage) or as average±standard deviation. 
Changes in metabolic status during follow-up were expressed as percentage and (95% 
confidence interval). Multivariable analysis was performed using logistic regression and the 
results were expressed as Odds ratio (OR) and 95% confidence interval (CI). When computing 
the ORs for CVRFs (HTN, T2DM, and dyslipidemia), results were adjusted for baseline age, 
sex, smoking status, education, and physical activity. For each CVRF, analyses were 
performed on participants devoid of the condition at baseline.  
As subjects who did not participate the follow-up differed from those who participated 
by a number of characteristics, a sensitivity analysis was performed. First, a propensity score 
was computed using nonparticipation in follow-up (coded as yes/no) as the dependent variable 
and gender, age, BMI, smoking, education, and physical activity as the independent variables. 
For each participant, the probability of nonparticipation was estimated and used in an inverse 
probability weighting model [22]. Statistical significance was assessed for a two-sided test with 
p<0.05. 
RESULTS 
Characteristics of participants 
Of the initial 6733 participants, 1645 (24.43%) were excluded because of metabolic 
disease, and 8 (0.12%) because of type 1 diabetes at baseline, leaving 5080 participants 
(75.45%) eligible, of whom 203 (3.0% of the initial sample) presented with history of 
cardiovascular disease. After excluding participants devoid of follow-up data, the final 
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analytical sample consisted of 3038 participants (45.2% of the initial sample). The reasons for 
exclusion are summarized in figure 1. Excluded participants were more likely to be older, male, 
current smokers, less educated, and not physically active and had a higher average BMI 
(Supplemental table 1). 
 The characteristics of the participants according to obesity status at baseline are 
summarized in table 1. MHO participants were significantly less educated and less likely to 
complete physical activity and had a higher mean BMI and higher blood pressure levels than 
MNHO, while no differences were found for total cholesterol and fasting glucose. 
Metabolic health 
The results regarding metabolic health at 5.6 and 10.9 years are summarized in table 
2. Of the initial 170 (5.6%) participants with MHO at baseline, 59 (34.7%) and 78 (45.9%) kept 
their status at 5.6 and 10.9 years follow-up, respectively. At 5.6 years follow-up, more than half 
of MHO participants became MUO, while at 10.9 years follow-up roughly 40% were classified 
as MUO. A small percentage of MHO participants at baseline became MHNO at first follow-up 
and second follow-up. A very small percentage of MHO participants at baseline became MUNO 
at either first or second follow-up. 
Females and males tended to follow similar trends, but more females remained MHO 
or became MHNO and more males became MUO at both first and second follow-ups. Similar 
trends across age groups were also observed, with the highest proportion of participants 
becoming MUO at first follow-up for all age groups except for ages 45-54 in which the 
percentage of those remaining MHO was the same as those who became MUO. At second 
follow-up, ages 35-54 were most likely to retain their MHO status and second most likely to be 
MUO while ages 55-75 were most likely to be MUO and secondarily MHO. 
At baseline, 2868 (94.4%) MHNO participants were identified, of which 2297 (80.1%) 
and 2340 (81.6%) remained MHNO at 5.6 and 10.9 years follow-up, respectively. At 5.6 years 
follow-up, 16.0% of MHNO participants at baseline became MUNO while at 10.9 years follow-
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up only 11.4% were MUNO. A small percentage of MHNO participants at baseline became 
MHO or MUO at first and second follow-ups. Females and males tended to follow similar 
patterns, but more females remained MHNO and more males became MUNO at both first and 
second follow-ups. Similar trends across age groups were also observed as most MHNO 
retained their MHNO status, but as age increased, the percentage of those remaining MHNO 
decreased at both follow-ups. Correspondingly, as age increased, the likelihood of being 
MUNO increased at both follow-ups with the exception of age group 65-75. 
Incidence of cardiovascular risk factors 
The results regarding the incidence of cardiovascular risk factors are summarized in 
table 3. In bivariate analysis, MHO participants had a higher incidence of T2DM, dyslipidemia 
and high triglycerides than MHNO participants at both follow-ups, while no association was 
found with HTN. MHO participants also had a higher incidence of low HDL or hypolipidemic 
drug treatment at 10.9 years follow-up. 
The associations between MHO and incidence of T2DM or dyslipidemia were further 
confirmed by multivariable analysis at both follow-ups, while the association with high 
triglycerides was only found at 5.6 years follow-up. Sensitivity analyses using inverse 
probability weighting for non-participation due to lack of follow-up confirmed the results, the 
effect of MHO on low HDL becoming significant also at 5.6 years follow-up (table 3). 
DISCUSSION 
Our results show that a considerable fraction of MHO individuals lose their status over 
time and that obesity significantly increases the risk of developing CVRFs in individuals who 
are initially metabolically healthy, a finding in agreement with two large studies conducted in 
the USA [23, 24]. Our results confirm that MHO should not be considered as a benign status, 
at least in the US and in Europe. 
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Metabolic health 
Almost half of participants who were MHO at baseline, versus approximately 20% of 
MHNO participants, lost their metabolically healthy status after 10.9 years follow-up. Despite 
using slightly modified criteria to define metabolic health and a follow-up period of 6 years, we 
nearly replicated Soriguer et al.’s results, which showed that roughly half of MHO participants 
at baseline remained MHO and roughly 20% of MHNO became metabolically unhealthy 6 
years later [25]. Furthermore, despite creating their own criteria to define metabolic health, 
Achilike et al. also found that almost half of those with MHO at baseline transformed into MUHO 
over 7.8 years of follow-up [13]. This stark difference between MHO and MHNO in maintaining 
their metabolic health over time illustrates the negative effect of obesity. Similar findings were 
obtained when the analyses were stratified by age and sex with two notable exceptions: more 
women than men retained their good metabolic health and the percentage of participants within 
each age group who retained good metabolic health decreased with age. These results support 
previous findings that the prevalence of metabolic abnormalities has a positive association with 
age [10] and that men have a higher prevalence of metabolic abnormalities [18]. 
In this way, we showed that the MHO phenotype is relatively unstable over 10 years. 
Yet, due to the lack of consensus on a gold standard definition of metabolic syndrome, it is 
difficult to compare our results across the literature. We used the JIS criteria including 
abdominal obesity, as was applied in several other studies [10, 12, 15, 26]. Despite using 
different definitions for metabolic health, other studies similarly revealed that the MHO 
condition is unstable [4, 5, 25, 26]. In fact, MHO status may be akin to a “grace period” that will 
inevitably end after a given time. We saw that MHO participants who remained metabolically 
healthy after 10.9 years follow-up were significantly younger and had lower CVRF levels than 
MHO participants who became metabolically unhealthy (Supplemental table 2). As a result, 
it appears likely that MHO status is only transient before obese individuals develop additional 
metabolic abnormalities that put them at higher risk for CVD, death, and other comorbidities.  
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Incidence of cardiovascular risk factors 
MHO participants had a higher likelihood of developing T2DM, low HDL or being on 
hypolipidemic medication, dyslipidemia, and high triglycerides depending on follow-up. When 
computing the relative incidence of CVRFs, we compared the MHO with individuals whose 
BMI was <30 kg/m2. However, most other studies compared the incidences of CVRFs between 
MHO and metabolically healthy individuals of normal weight (BMI<25 kg/m2). Thus, the 
differences between MHO and MHNO participants should be smaller in our study, as the effect 
of overweight status (25<BMI<30 kg/m2) was not present in the other studies. Still, our findings 
were similar to previous work regarding incidence of T2DM [14, 15, 27-29] and dyslipidemia 
(both hypertriglyceridemia and low HDL-c) [30] even though these studies used metabolically 
healthy normal weight individuals as a reference and modified criteria to define metabolic 
health. In addition, one study that used slightly modified criteria to define metabolic health and 
HbA1c levels to diagnose diabetes but compared the incidence of T2DM in MHO with BMI≥30 
kg/m2 with that in MHNO with BMI<30 kg/m2 also found a higher incidence of T2DM in MHO 
individuals over 6 and 11 years of follow-up [25]. 
No difference was found between MHO and MHNO participants regarding the 
incidence of HTN, defined as either ≥130/85 or ≥140/90 mm Hg. A likely explanation resides 
in the small sample size, which led to a reduced statistical power. Indeed, the RR were 
compatible with an increased risk of developing HTN, although the association was not 
statistically significant. Interestingly, other studies also suggested that the impact of MHO on 
diabetes might be stronger (or occur sooner) than for other cardiovascular risk factors [24], the 
lowest RR being found for HTN. Chang et al., though using the same criteria to define 
metabolic syndrome, witnessed a significantly increased risk for pre-hypertension (defined as 
≥130/85 mm Hg) in MHO individuals compared with metabolically healthy normal weight 
individuals [30]. Similarly, Lee et al., though using different criteria to define metabolic health, 
found a higher incidence of HTN (defined as ≥140/90 mm Hg) in healthy obese compared with 
healthy normal weight individuals [31]. Our results may not indicate this association by virtue 
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of our inclusion of overweight individuals into our reference group and/or our small number of 
MHO participants.  
Strengths and limitations 
Strengths of our study include a 10-year follow-up period. Additionally, given our fairly 
homogenous study population, we were able to apply strict criteria to define metabolic health 
and thus metabolic syndrome, contrary to previous studies that did not take waist 
circumference into account [14, 25, 27, 28]. Moreover, our study outlined incidences for 
multiple specific CVRFs, as opposed to examining endpoints of all-cause mortality or CVD [6, 
12, 29]. Our study also not only assessed the natural course of the MHO phenotype for CVRFs 
but additionally compared its natural course to that of the MHNO phenotype taken from the 
same source population, contrary to the many other studies that compared MHO individuals 
to metabolically healthy normal weight individuals [14, 15, 27-29]. Finally, to our knowledge, 
our study is one of few that looked specifically at the incidence of HTN in MHO individuals as 
compared with that in MHNO individuals. 
Our study also has several limitations. First, our relatively small number of MHO 
(N=179) limited our statistical power. This is a common finding in most studies on MHO, as 
this condition is relatively infrequent: 2.9% in one study of subjects aged 45 to 64 [24] and 10% 
in a study of subjects aged 18 to 65 [23]). This small number was partly due to the large number 
of participants without follow-up data; further, participants without follow-up data presented 
more frequently with MHO than included participants (supplemental table 3). Also, 
participants devoid of follow-up were significantly older, more frequently men, current smokers 
and of lower educational level, were less physically active and had a higher BMI. Hence, it is 
likely that the incidence of cardiovascular risk factors (and thus the change in status from MHO 
to MUO) would have been higher had these participants been included in the analyses. 
Further, the retained sample can no longer be considered as representative of the original 
population, so generalizability to other populations is limited. Still, our results apply to 
participants with MHO who are within the age range studied, as other studies that focused on 
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this condition report similar findings [23, 24]. Overall, and despite the use of a propensity score 
to correct for selection bias, our results might underestimate the true impact of MHO on the 
incidence of cardiovascular and metabolic risk factors. We also did not collect information 
regarding bariatric surgery, which could explain why some MHO lost weight, becoming MHNO 
or MUNO. However, the relatively low number of MHO subjects becoming MHNO or MUNO at 
the second follow-up would likely not affect the significance of our results. Additionally, when 
calculating the incidence of T2DM, we did not use HbA1c values due its lack of availability; 
instead, we defined those participants with a fasting plasma glucose ≥7.0 mmol/L to have 
T2DM. Yet, studies have shown that there exists a significant correlation between FPG and 
HbA1c values so our conclusions would likely remain had we used HbA1c values [32, 33]. 
Finally, this study enrolled only Caucasian participants, which might limit the generalization of 
our findings to other ethnic groups. However, studies across multiple other ethnic groups also 
revealed a higher incidence of CVRFs in the MHO group [23, 24, 29] and instability of the MHO 
phenotype [5]. 
Conclusion 
Being obese yet metabolically healthy leads to a higher risk of developing CVRFs as 
compared with being metabolically healthy and not obese. Our study supports that the MHO 
state is transient and should be regarded by clinicians as a warning sign. 
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FIGURE LEGENDS 
Figure 1: selection procedure, Colaus study, Lausanne, Switzerland. 
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TABLES 
Table 1: Characteristics of metabolically healthy non-obese and metabolically healthy obese 
participants at baseline (2003-2006), Colaus study, Lausanne, Switzerland. 
 MHNO (N=2868) MHO (N=170) p-value 
Age (years) 49.9 ± 9.9 49.4 ± 9.7 0.486 
Female sex 1658 (57.8) 95 (55.9) 0.621 
Smoking status   0.158 
 Never 1241 (43.3) 73 (42.9)  
 Former 895 (31.2) 63 (37.1) 
 Current 732 (25.5) 34 (20.0) 
Education    <0.001 
 University 741 (25.8) 22 (12.9)  
 High school 806 (28.1) 37 (21.8) 
 Apprenticeship 945 (33.0) 64 (37.7) 
 Mandatory  376 (13.1) 47 (27.7) 
Physically active 1732 (60.4) 76 (44.7) <0.001 
Body mass index (kg/m2) 23.7 ± 2.8 32.8 ± 3.0 <0.001 
SBP (mm Hg) 123 ± 16 127 ± 16 0.002 
DBP (mm Hg) 77 ± 10 82 ± 10 <0.001 
Total cholesterol (mmol/L) 5.5 ± 1.0 5.6 ± 1.1 0.455 
Fasting glucose (mmol/L) 5.2 ± 0.6 5.3 ± 0.5 0.084 
MHO, metabolically healthy obese; MHNO, metabolically healthy non-obese; SBP, systolic 
blood pressure; DBP, diastolic blood pressure. Results are expressed as number of 
participants (percentage) or as mean ± standard deviation. Between-group comparisons 
performed using student’s t-test or chi square analysis. 
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Table 2: Prevalence of metabolically healthy obesity and metabolically healthy non-obesity, overall and stratified by sex or age group, 2006-
2017, Colaus study, Lausanne, Switzerland. 
Baseline Status   First follow-up Second follow-up 
N MHNO MHO MUNO MUO MHNO MHO MUNO MUO 
MHO          
Total 170 9.4 
(5.5 - 14.8) 
34.7 
(27.6 - 42.4) 
2.4 
(0.6 - 5.9) 
53.5 
(45.7 - 61.2) 
13.5 
(8.8 - 19.6) 
45.9 
(38.2 - 53.7) 
1.8 
(0.4 - 5.1) 
38.8 
(31.5 - 46.6) 
By sex          
Female 95 12.6 
(6.7 - 21.0) 
38.9 
(29.1 - 49.5) 
3.2 
(0.7 – 9.0) 
45.3 
(35.0 - 55.8) 
15.8 
(9.1 - 24.7) 
49.5 
(39.1 - 59.9) 
2.1 
(0.3 - 7.4) 
32.6 
(23.4 – 43.0) 
Male 75 5.3 
(1.5 - 13.1) 
29.3 
(19.4 - 41.0) 
1.3 
(0 - 7.2) 
64.0 
(52.1 - 74.8) 
10.7 
(4.7 - 19.9) 
41.3 
(30.1 - 53.3) 
1.3 
(0 - 7.2) 
46.7 
(35.1 - 58.6) 
Age group (years)          
35-44 67 9.0 
(3.4 - 18.5) 
41.8 
(29.8 - 54.5) 
1.5 
(0 – 8.0) 
47.8 
(35.4 - 60.3) 
11.9 
(5.3 - 22.2) 
50.7 
(38.2 - 63.2) 
3.0 
(0.4 - 10.4) 
34.3 
(23.2 - 46.9) 
45-54 57 12.3 
(5.1 - 23.7) 
42.1 
(29.1 - 55.9) 
0 
(0 – 6.3) 
45.6 
(32.4 - 59.3) 
7.0 
(1.9 - 17) 
52.6 
(39.0 – 66.0) 
1.8 
(0 - 9.4) 
38.6 
(26 - 52.4) 
55-64 31 6.5 
(0.8 - 21.4) 
16.1 
(5.5 - 33.7) 
6.5 
(0.8 - 21.4) 
71.0 
(52.0 - 85.8) 
25.8 
(11.9 - 44.6) 
29.0 
(14.2 - 48) 
0 
(0 – 11.2) 
45.2 
(27.3 - 64) 
65-75 15 6.7 
(0.2 - 31.9) 
13.3 
(1.7 - 40.5) 
6.7 
(0.2 - 31.9) 
73.3 
(44.9 - 92.2) 
20.0 
(4.3 - 48.1) 
33.3 
(11.8 - 61.6) 
0 
(0 – 21.8) 
46.7 
(21.3 - 73.4) 
MHNO          
Total 2868 80.1 
(78.6 - 81.5) 
1.8 
(1.4 - 2.4) 
16.0 
(14.6 - 17.4) 
2.1 
(1.6 - 2.7) 
81.6 
(80.1 – 83.0) 
3.9 
(3.3 - 4.7) 
11.4 
(10.2 - 12.6) 
3.1 
(2.5 - 3.8) 
By sex          
Female 1658 83.1 
(81.2 - 84.9) 
1.9 
(1.3 - 2.6) 
13.3 
(11.7 – 15.0) 
1.7 
(1.2 - 2.5) 
84.7 
(82.9 - 86.4) 
4.7 
(3.7 - 5.8) 
8.4 
(7.1 - 9.8) 
2.2 
(1.6 - 3.1) 
Male 1210 76.0 1.8 19.7 2.6 77.4 2.9 15.5 4.3 
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(73.4 - 78.3) (1.1 - 2.7) (17.5 – 22.0) (1.7 - 3.6) (74.9 - 79.7) (2.0 – 4.0) (13.5 - 17.6) (3.2 - 5.6) 
Age group (years)          
35-44 1063 87.2 
(85.0 - 89.2) 
2.5 
(1.7 - 3.7) 
8.7 
(7.1 - 10.6) 
1.5 
(0.9 - 2.4) 
84.4 
(82.1 - 86.5) 
5.2 
(3.9 - 6.7) 
7.3 
(5.8 - 9.1) 
3.1 
(2.1 - 4.3) 
45-54 922 82.4 
(79.8 - 84.8) 
1.6 
(0.9 - 2.7) 
14.1 
(11.9 - 16.5) 
1.8 
(1.1 - 2.9) 
80.8 
(78.1 - 83.3) 
3.0 
(2.0 - 4.4) 
12.8 
(10.7 - 15.1) 
3.4 
(2.3 - 4.7) 
55-64 642 70.7 
(67.0 - 74.2) 
1.4 
(0.6 - 2.6) 
24.8 
(21.5 - 28.3) 
3.1 
(1.9 - 4.8) 
80.4 
(77.1 - 83.4) 
3.3 
(2.0 – 5.0) 
12.9 
(10.4 - 15.8) 
3.4 
(2.2 - 5.1) 
65-75 241 64.7 
(58.3 - 70.8) 
0.8 
(0.1 - 3.0) 
31.5 
(25.7 - 37.8) 
2.9 
(1.2 - 5.9) 
75.5 
(69.6 - 80.8) 
3.7 
(1.7 – 7.0) 
19.5 
(14.7 - 25.1) 
1.2 
(0.3 - 3.6) 
MHO, metabolically healthy obese; MHNO, metabolically healthy non-obese; MUO, metabolically unhealthy obese; MUNO, metabolically 
unhealthy non-obese. Results are expressed as percentage and (95% confidence interval). 
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Table 3: Incidence of hypertension, type 2 diabetes mellitus, dyslipidemia, high triglycerides and low HDL-cholesterol or hypolipidemic drug 
treatment at the first and the second follow-up, in metabolically healthy obese and metabolically healthy non-obese participants, Colaus study, 
Lausanne, Switzerland.    
  First follow-up Second follow-up 
 N Bivariate Multivariable Multivariable § Bivariate Multivariable Multivariable § 
HTN (≥140/90 mm Hg)        
MHNO 2310 347 (15.0) 1.0 (ref.) 1.0 (ref.) 519 (22.5) 1.0 (ref.) 1.0 (ref.) 
MHO 111 22 (19.8) 1.39 (0.84 - 2.31) 1.34 (0.79 - 2.26) 31 (27.7) 1.19 (0.76 - 1.85) 1.11 (0.70 - 1.74) 
p-value  0.169 0.201 0.280 0.200 0.445 0.665 
HTN (≥130/85 mm Hg)        
MHNO 1928 394 (20.4) 1.0 (ref.) 1.0 (ref.) 510 (26.5) 1.0 (ref.) 1.0 (ref.) 
MHO 94 26 (27.7) 1.43 (0.88 - 2.33) 1.44 (0.87 - 2.38) 32 (34.0) 1.29 (0.82 - 2.05) 1.30 (0.80 - 2.09) 
p-value  0.092 0.154 0.161 0.105 0.272 0.286 
Type 2 diabetes        
MHNO 2834 62 (2.2) 1.0 (ref.) 1.0 (ref.) 62 (2.2) 1.0 (ref.) 1.0 (ref.) 
MHO 164 8 (4.9) 2.31 (1.05 - 5.08) 2.42 (1.06 - 5.50) 14 (8.5) 4.01 (2.12 - 7.58) 4.45 (2.23 - 8.88) 
p-value  0.027 0.037 0.036 <0.001 <0.001 <0.001 
Dyslipidemia        
MHNO 2339 445 (19.0) 1.0 (ref.) 1.0 (ref.) 508 (21.7) 1.0 (ref.) 1.0 (ref.) 
MHO 134 42 (31.3) 1.83 (1.24 - 2.70) 1.90 (1.27 - 2.85) 43 (32.1) 1.61 (1.10 - 2.37) 1.65 (1.10 - 2.47) 
p-value  <0.001 0.002 0.002 0.005 0.015 0.015 
Low HDL or Rx        
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MHNO 2639 334 (12.7) 1.0 (ref.) 1.0 (ref.) 482 (18.3) 1.0 (ref.) 1.0 (ref.) 
MHO 150 27 (18.0) 1.52 (0.98 - 2.38) 1.66 (1.04 - 2.66) 40 (26.7) 1.59 (1.08 - 2.33) 1.66 (1.11 - 2.50) 
p-value  0.058 0.063 0.034 0.010 0.018 0.014 
High triglycerides        
MHNO 2532 258 (10.2) 1.0 (ref.) 1.0 (ref.) 201 (7.9) 1.0 (ref.) 1.0 (ref.) 
MHO 151 31 (20.5) 2.05 (1.33 - 3.15) 1.94 (1.27 - 2.97) 19 (12.6) 1.52 (0.91 - 2.54) 1.40 (0.82 - 2.39) 
p-value  <0.001 0.001 0.002 0.043 0.110 0.212 
MHO, metabolically healthy obese; MHNO, metabolically healthy non-obese; HTN, hypertension; Rx, hypolipidemic drug treatment. Type 2 
diabetes was defined as fasting plasma glucose of ≥7.0 mmol/L and/or anti-diabetic drug treatment. Dyslipidemia was defined as fasting HDL-C 
<1.30 mmol/L in women and <1.00 mmol/L in men and/or high triglycerides (defined as fasting TG ≥1.7 mmol/L) and/or hypolipidemic drug 
treatment. Results are expressed as number of participants (%) or as odds-ratio [95% confidence interval]. For each risk factor, analyses were 
performed on participants devoid of the condition at baseline. Bivariate analysis was done using chi-square; multivariable analysis was done 
using logistic regression adjusting for baseline age, sex, smoking status, education, and physical activity. § Sensitivity analyses were conducted 
using inverse probability weighting for non-participation due to lack of follow-up. P-values relate to the chi-square for bivariate analyses and to 
the odds-ratio for multivariable analyses. 
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Highlights 
• Over half of metabolically health obese individuals lose their status over time 
• In metabolically healthy adults, obesity increases risk of dyslipidemia by 64% 
• In metabolically healthy adults, obesity increases risk of diabetes by 240% 
• In metabolically healthy adults, obesity did not increase risk of hypertension 
 
 
